TAK, US8740602052

Takeda stock: BofA raises target to USD 26.70

Published on 11/17/2026 at 15:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Takeda stock drew a higher Bank of America target after the analyst reviewed quarterly results, Orzeyful pricing and foreign-exchange assumptions. The Buy rating stayed in place.

What changed for Takeda investors

  • Bank of America kept its Buy rating after updating its outlook for Takeda.
  • The revised view reflects second-quarter results, Orzeyful pricing and foreign-exchange assumptions.
TAK, US8740602052, Illustration mit AI erstellt.

Bank of America analyst Koichi Mamegano raised the firm's price target for Takeda to USD 26.70 from USD 21.90 on November 16, 2026, while keeping a Buy rating on the shares. Markets Insider reported that the revised forecasts reflect Takeda's second-quarter results, Orzeyful prices and changes to foreign-exchange assumptions.

Analyst view shifts higher

The move gives investors a fresh sell-side assessment following Takeda's latest quarterly update. The unchanged Buy rating signals that the target revision was accompanied by a continued positive view of the shares, while the forecast changes point to operating results, pricing and currency assumptions as the main factors in the update.

Trading snapshot

Takeda stock traded at 19.50 euros on Lang & Schwarz at 15:13 CET on Tuesday, November 17, 2026. The quoted level provides a live-market reference for investors following the US-listed security while the analyst target remains denominated in US dollars.

Takeda Pharmaceutical Company

  • ISIN: US8740602052
  • Ticker: TAK
  • Trading venue: Lang & Schwarz
  • Quoted price: 19.50 euros at 15:13 CET on November 17, 2026

Broader US market developments are covered in Current market reports.

More news and analyses on Takeda stock

Disclaimer...
en | US8740602052 | TAK | boerse | 70527356 | bgmi